What Should MDS Patients Know about Stem Cell Transplants with Dr. Brian Ball image

What Should MDS Patients Know about Stem Cell Transplants with Dr. Brian Ball

Can't make it to the event?
We send a recording to all registered participants of the event!
Nov 17, 2026
01:00PM - 02:00PM EST
Online Event
Overview

Join the HealthTree Foundation for this webinar focused on stem cell transplants for the MDS community. This is a wonderful opportunity to hear from Dr. Brian Ball from City of Hope in Duarte, California a MDS expert about the key things that MDS patients should know. Join us live to ask questions to Dr. Ball. Can't attend? We encourage you to still register in order to receive the event recording emailed directly to you.

Agenda
1:00 PM
Introduction
Dalton Bean

Dalton introduces the agenda for the event and the speaker Brian Ball, MD

1:05 PM
Presentation
Brian Ball, MD

Dr. Ball shares about stem cell transplant for MDS patients

1:35 PM
Questions & Answers
Audience

Come prepared to learn and ready to ask questions!

Speakers & Moderators
Healthtree contact Dalton Bean

Dalton Bean

Dalton joined HealthTree in 2024 as the MPNs and MDS Program Manager. He is passionate about helping patients gain a better understanding of their health and treatment and sees it as a way to help empower individuals and their families who are affected by these diseases. Prior to joining HealthTree Dalton earned a Master’s Degree in Oncological Sciences while studying various different blood cancers. When not interacting with patients he is an avid snowboarder and hiker.
Healthtree contact Brian Ball, MD

Brian Ball, MD

Dr. Ball is a hematologist-oncologist specializing in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and other myeloid malignancies at City of Hope. His research focuses on the molecular mechanisms of resistance to leukemia therapies, including strategies to overcome resistance to apoptosis-based treatments. His published research also includes venetoclax-based therapies, FLT3 and IDH1/2 inhibitors, KMT2A-rearranged AML, and treatment approaches surrounding stem-cell transplantation. His work integrates laboratory investigation with the development and evaluation of therapeutic strategies for patients with difficult-to-treat leukemias.